About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

GNI Group Ltd.(2160) Summary

2160
TSE Growth
GNI Group Ltd.
1,741
JPY
-141
(-7.49%)
Apr 4, 3:30 pm JST
11.91
USD
Apr 4, 2:30 am EDT
Result
PTS
outside of trading hours
1,640
Apr 4, 11:57 pm JST
Summary Chart Historical News Financial Result
PER
7.2
PBR
2.40
Yield
ー%
Margin Trading Ratio
41.51
Stock Price
Apr 4, 2025
Opening Apr 4, 9:00 am
1,846 JPY 12.62 USD
Previous Close Apr 3
1,882 JPY 12.78 USD
High Apr 4, 9:00 am
1,860 JPY 12.71 USD
Low Apr 4, 1:52 pm
1,636 JPY 11.24 USD
Volume
5,249,300
Trading Value
9.06B JPY 0.06B USD
VWAP
1724.99 JPY 11.81 USD
Minimum Trading Value
174,100 JPY 1,191 USD
Market Cap
0.09T JPY 0.60B USD
Number of Trades
12,369
Liquidity & Number of Trades
As of Apr 4, 2025
Liquidity
High
1-Year Average
3,557
1-Year High Mar 5, 2025
28,291
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 28, 2025 123,400 5,638,400 45.69
Mar 21, 2025 68,900 5,635,700 81.80
Mar 14, 2025 103,600 5,415,500 52.27
Mar 7, 2025 58,000 5,371,900 92.62
Feb 28, 2025 113,600 5,042,000 44.38
Company Profile
GNI Group Ltd. is a biotech venture company focused on drug discovery. It has research and development centers in the United States and China. The company's main product is a drug for idiopathic pulmonary fibrosis. They are also involved in genetic analysis.
Sector
Pharmaceuticals
GNI Group Ltd. operates in both the pharmaceutical and medical device sectors. In its pharmaceutical business, the company sells F351 (Etuary), a treatment for fibrosis, in the Chinese market. They also conduct research, development, manufacturing, and sales of drug compounds targeting lung diseases (interstitial lung diseases), liver diseases, and kidney diseases (chronic kidney disease). The medical device business is based in the United States and focuses on the development, manufacturing, and sales of biomaterials. The group consists of the parent company, 18 consolidated subsidiaries, and 2 affiliated companies. They also provide services such as reagents, designated manufacturing and marketing of medical devices, and domestic clinical trial management.